Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy- United Kingdom

doi 10.1517/14656566.2014.923404

Full Text

Abstract

Available in

Categories

Date

May 24, 2014

Authors

Fabio PS Santos

Srdan Verstovsek

Publisher

Informa Healthcare

Related search

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology

English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy

English

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine

English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal

English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

English

Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis

OncoTargets and Therapy

English

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research

Cancer Research

English